We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+233.54%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$660M
AUM Growth
+$204M
Cap. Flow
-$95.2M
Cap. Flow %
-14.43%
Top 10 Hldgs %
71.28%
Holding
34
New
4
Increased
8
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$8.26M
2
CDTX
Cidara Therapeutics
CDTX
+$6.38M
3
KYMR icon
Kymera Therapeutics
KYMR
+$4.24M
4
ABVX
Abivax
ABVX
+$3.56M
5
OCUL icon
Ocular Therapeutix
OCUL
+$2.38M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$31.9M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$23.6M
3
ATYR
aTyr Pharma
ATYR
+$19.4M
4
TRML
Tourmaline Bio
TRML
+$14.5M
5
NUVB icon
Nuvation Bio
NUVB
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11B
$112M 17.05%
1,325,000
+58,000
+5% +$3.56M
DNTH icon
2
Dianthus Therapeutics
DNTH
$5.68B
$95.1M 14.41%
2,416,667
+75,000
+3% +$1.92M
GOSS icon
3
Gossamer Bio
GOSS
$66.5M
$44.8M 6.8%
17,050,000
-1,300,000
-7% -$2.87M
COGT icon
4
Cogent Biosciences
COGT
$6.79B
$41.3M 6.26%
2,874,111
+111,111
+4% +$1.32M
AVBP icon
5
ArriVent BioPharma
AVBP
$1.48B
$36.4M 5.51%
1,971,054
+25,000
+1% +$491K
OCUL icon
6
Ocular Therapeutix
OCUL
$1.86B
$30.7M 4.65%
2,624,000
+199,000
+8% +$2.38M
TSHA icon
7
Taysha Gene Therapies
TSHA
$1.59B
$29.7M 4.49%
9,067,500
-3,525,000
-28% -$9.98M
MRUS
8
DELISTED
Merus
MRUS
$29M 4.4%
308,000
-81,000
-21% -$5.28M
TRVI icon
9
Trevi Therapeutics
TRVI
$2.49B
$25.8M 3.9%
2,815,000
-857,000
-23% -$6.43M
DFTX
10
Definium Therapeutics
DFTX
$5.73B
$25.1M 3.81%
2,130,000
– –
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$20.4M 3.1%
903,500
– –
KYMR icon
12
Kymera Therapeutics
KYMR
$9.1B
$20.4M 3.09%
360,000
+94,000
+35% +$4.24M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$20.1M 3.05%
830,000
-200,000
-19% -$3.55M
CDTX
14
CALL
DELISTED
Cidara Therapeutics
CDTX
$19.2M 2.9%
+200,000
New +$12.8M
PHVS icon
15
Pharvaris
PHVS
$2.39B
$18M 2.73%
722,595
+50,000
+7% +$1.11M
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$15.5M 2.35%
1,273,333
– –
CRBP icon
17
Corbus Pharmaceuticals
CRBP
$170M
$14.1M 2.14%
1,115,000
– –
BBOT
18
BridgeBio Oncology
BBOT
$707M
$12.1M 1.83%
1,043,110
+793,110
+317% +$8.26M
DBVT
19
DBV Technologies
DBVT
$807M
$10.2M 1.54%
1,018,021
– –
NUVB icon
20
Nuvation Bio
NUVB
$2.24B
$9.74M 1.48%
2,633,334
-5,058,000
-66% -$13.8M
CDTX
21
DELISTED
Cidara Therapeutics
CDTX
$9.58M 1.45%
+100,000
New +$6.38M
MAZE
22
Maze Therapeutics
MAZE
$1.53B
$4.61M 0.7%
177,667
– –
NGNE icon
23
Neurogene
NGNE
$696M
$4.37M 0.66%
252,000
-51,000
-17% -$1.02M
UNCY icon
24
Unicycive Therapeutics
UNCY
$148M
$4.36M 0.66%
1,000,000
– –
PEPG icon
25
PepGen
PEPG
$133M
$3.23M 0.49%
+700,000
New +$1.13M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Octagon Capital Advisors held 34 positions worth $660M, up 45% from $456M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Octagon Capital Advisors withdrew a net $95.2M in Q3 2025, closing 7 positions and reducing 8 holdings. Its most notable exit was Verona Pharma, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

Against the trend, Octagon Capital Advisors opened a new position in Cidara Therapeutics worth $9.58M.

  • Octagon Capital Advisors's largest Q3 2025 buy was Cidara Therapeutics: 100,000 shares worth $9.58M.
  • Octagon Capital Advisors added most to BridgeBio Oncology in Q3 2025, an estimated $8.26M increase.
  • Octagon Capital Advisors's biggest Q3 2025 reduction was Nuvation Bio, cutting an estimated $13.8M.
  • Octagon Capital Advisors fully exited Verona Pharma in Q3 2025, selling an estimated $31.9M.
  • Octagon Capital Advisors's ten largest holdings make up 71% of its $660M portfolio in Q3 2025.
  • Octagon Capital Advisors opened 4 new positions and closed 7 in Q3 2025.
  • Octagon Capital Advisors's portfolio value rose 45% quarter-over-quarter to $660M.

Based on Octagon Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.